Drug intelligence / Profile preview

M-267

Development stage: Preclinical
Lead developer: Johnson & Johnson
Modality: Small Molecules

Overview

M-267 is a **CD38 inhibitor** developed by Momenta Pharmaceuticals. Its mechanism of action is the inhibition of **CD38**, an ectoenzyme involved in the metabolism of NAD+ and calcium signaling, which plays a critical role in immune regulation and is a validated target in certain hematologic malignancies such as multiple myeloma. As of the latest available information, M-267 remains in preclinical development[2].

Targets

CD38 (Cluster of Differentiation 38)

Beyond the preview

Go deeper on M-267.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on M-267.

Explore the full profile